0001179022-18-000069.txt : 20180904
0001179022-18-000069.hdr.sgml : 20180904
20180904160855
ACCESSION NUMBER: 0001179022-18-000069
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180830
FILED AS OF DATE: 20180904
DATE AS OF CHANGE: 20180904
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Rubin Marc
CENTRAL INDEX KEY: 0001412377
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-31791
FILM NUMBER: 181052468
MAIL ADDRESS:
STREET 1: C/O TITAN PHARMACEUTICALS, INC.
STREET 2: 400 OYSTER POINT BLVD., STE 505
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: GALECTIN THERAPEUTICS INC
CENTRAL INDEX KEY: 0001133416
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043562325
STATE OF INCORPORATION: NV
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4960 PEACHTREE INDUSTRIAL BOULEVARD
STREET 2: SUITE 240
CITY: NORCROSS
STATE: GA
ZIP: 30071
BUSINESS PHONE: 678-620-3186
MAIL ADDRESS:
STREET 1: 4960 PEACHTREE INDUSTRIAL BOULEVARD
STREET 2: SUITE 240
CITY: NORCROSS
STATE: GA
ZIP: 30071
FORMER COMPANY:
FORMER CONFORMED NAME: PRO PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20010612
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2018-08-30
0001133416
GALECTIN THERAPEUTICS INC
GALT
0001412377
Rubin Marc
C/O GALECTIN THERAPEUTICS, INC.
4960 PEACHTREE INDUSTRIAL BLVD., STE 240
NORCROSS
GA
30071
1
0
0
0
Common Stock
2018-08-30
4
M
0
29000
0
A
84581
D
Common Stock
2018-08-30
4
S
0
58100
6.0811
D
26481
D
Stock option (right to buy)
.89
2018-08-30
4
M
0
29000
0
D
2026-12-15
Common Stock
29000
22500
D
The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 10, 2018.
The options vested 100% on December 14, 2017, the date of Galectin Therapeutics, Inc.'s 2017 Annual Stockholders Meeting.
The shares were sold in multiple transactions at prices ranging from $6.00 to $6.53. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
/s/ Jack W. Callicutt, by power of attorney
2018-09-04